The study investigates the effects of AS-2, a potent inhibitor of kinesin activity, on Drosophila embryos. AS-2 specifically inhibits kinesin by interfering with microtubule (MT) binding, a mechanism distinct from known kinesin inhibitors. Embryos injected with AS-2 exhibited various phenotypes, including failure to develop past the gastrula stage, indicating that AS-2 cannot cross cell membranes. The results suggest that AS-2 and its derivatives have potential applications as antimotinic or antitransport drugs, therapeutic agents, and tools for studying kinesin functions. The ability of AS-2 to mimic MT activity also opens up possibilities for creating artificial kinesin tracks and modifying surfaces for kinesin-based applications.The study investigates the effects of AS-2, a potent inhibitor of kinesin activity, on Drosophila embryos. AS-2 specifically inhibits kinesin by interfering with microtubule (MT) binding, a mechanism distinct from known kinesin inhibitors. Embryos injected with AS-2 exhibited various phenotypes, including failure to develop past the gastrula stage, indicating that AS-2 cannot cross cell membranes. The results suggest that AS-2 and its derivatives have potential applications as antimotinic or antitransport drugs, therapeutic agents, and tools for studying kinesin functions. The ability of AS-2 to mimic MT activity also opens up possibilities for creating artificial kinesin tracks and modifying surfaces for kinesin-based applications.